In this view, it is noteworthy how the UniPR1331 treatment was able to reduce the expression of the fatty acid synthase (FASN), as the dysregulation of lipid metabolism via FASN overexpression is considered to be a hallmark of prostate cancer progression [28]. This evidence concerns the gene FASN and prostate carcinoma.